CORE-VNS

  • Research type

    Research Study

  • Full title

    Comprehensive Outcomes Registry in Subjects with Epilepsy Treated with Vagus Nerve Stimulation Therapy®

  • IRAS ID

    242687

  • Contact name

    Jason Jones

  • Contact email

    Jason.Jones@livanova.com

  • Sponsor organisation

    LivaNova Inc USA

  • Clinicaltrials.gov Identifier

    NCT03529045

  • Duration of Study in the UK

    8 years, 8 months, 7 days

  • Research summary

    Research Summary:

    Vagus Nerve Stimulation (VNS) Therapy has been CE Marked for the treatment of epilepsy non-responding to the pharmacological traetment since 1994 and FDA approved since 1997. This post-market observational registry is designed to collect data on the standard of care clinical course and outcomes for patients with refractory seizures treated with adjunctive VNS Therapy.
    Outcomes related to seizure severity and frequency, safety, quality of life, sleep and healthcare utilization will be documented and evaluated. The results of this study will provide data to guide physicians, the patients and the company in the use of VNS Therapy.

    Summary of results:

    The results of this study indicate that VNS Therapy is both safe and effective, leading to improvements in seizure frequency, severity, post-ictal severity, and quality of life, as well as reductions in healthcare resource utilization. No worsening in sleep quality was observed. Subgroup analyses showed that the early use of VNS Therapy (by age, by epilepsy years, and by ASMs) can significantly impact the degree of focal seizure reduction while the robust reduction of generalized seizures associated with VNS Therapy does not display the same time-dependent impact. VNS Therapy remains the least invasive surgical intervention in epilepsy. VNS Therapy remains the least invasive surgical intervention for drug-resistant epilepsy, with an excellent safety profile.

    https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Ftrack.pstmrk.it%2F3ts%2Fwww.ncbi.nlm.nih.gov%252Fpmc%252Farticles%252FPMC8705076%252F%2FNBTI%2FhInAAQ%2FAQ%2F8542ed45-cc30-4de2-811b-804e25f33449%2F1%2FFg_txAeRyq&data=05%7C02%7Charrow.rec%40hra.nhs.uk%7C978ef0dd50cf41018fa308de0589d74c%7C8e1f0acad87d4f20939e36243d574267%7C0%7C0%7C638954286763008141%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=TfCTpJnYm8c5WTfr0FJMU3ajRUJCEFWqh0ovYymd4%2F8%3D&reserved=0

  • REC name

    London - Harrow Research Ethics Committee

  • REC reference

    18/LO/0552

  • Date of REC Opinion

    27 Jun 2018

  • REC opinion

    Further Information Favourable Opinion